AFP confers the resistance of lenvatinib in hepatocellular carcinoma by activating PI3K/AKT/LDHA signaling axis. - Xing W; Wang F; Feng S; Li X; Zhou Y; Wu H; Lin B; Dong X; Li M; Zhu M (Discover oncology, 2026)